LIVING WITH CRC
Measurable residual disease testing enables earlier recurrence detection and personalized surveillance after treatmentMRD testing using circulating tumor DNA can identify patients at higher risk of recurrence before disease becomes clinically apparent, potentially guiding adjuvant treatment decisions and reducing uncertainty during post-treatment surveillance. (The ASCO Post)